Revealing Pharmacokinetic Interactions of Tramadol, Tapentadol, and Venlafaxine: A Cutting-Edge Liquid Chromatography–Tandem Mass Spectrometry Analytical Approach in Rat Plasma
- 19 March 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (4) , 1116-1128
Abstract
The detection and quantification of opioid analgesics adulterated with serotonin reuptake inhibitors are critical in forensic toxicology due to their significant clinical and legal implications. This study focuses on developing and validating a highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of tramadol (TMD), tapentadol (TAP), and venlafaxine (VEN) in small volumes of rat plasma. The method employs a straightforward single-step protein precipitation technique for sample pretreatment. Utilizing a Shim-pack Velox SP-C18 column (2.7 μm, 2.1 × 150 mm, Shimadzu, Japan), a 12 min gradient elution was performed with a mobile phase of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B). Detection and quantification were achieved in multiple-reaction-monitoring mode, with ion transitions of m/z 264.3 → 58.1 for TMD, m/z 222.3 → 107.1 for TAP, m/z 278.2 → 58.2 for VEN, and m/z 195.5 → 138.1 for caffeine, which served as the internal standard (IS). The method exhibited excellent linearity, with concentration ranges of 1-500 ng/mL for TMD (r 2 = 0.9981), 1-1000 ng/mL for TAP (r 2 = 0.9972), and 1-900 ng/mL for VEN (r 2 = 0.9987) in rat plasma using only 50 μL of sample. This validated method was applied to a pharmacokinetic interaction study, revealing significant drug interactions: the maximum observed plasma concentration (C max) and area under the curve (AUC) for both TMD and VEN decreased. For TMD, C max decreased by 2.58-fold from 276.25 to 106.99, and AUC0-t decreased by 1.4-fold from 3005.8 to 2159.3. For VEN, C max decreased by 2.51-fold from 494 to 191, and AUC0-t decreased by 2.3-fold from 4988 to 2114. However, for TAP, C max increased by 3.4-fold from 138.54 to 471.85, and AUC0-t increased by 2.66-fold from 1060.1 to 2826.8. The concurrent administration likely creates metabolic competition at CYP2D6 and UDP glycosyltransferase enzyme sites, affecting the pharmacokinetic parameters. These findings underscore the importance of further studies to monitor the simultaneous presence of these drugs and their metabolites in plasma, especially when coadministration occurs unintentionally.Keywords
This publication has 52 references indexed in Scilit:
- A high-throughput UPLC-MS-MS Bio-analytical method for the analysis of veterinary pharmaceutical residues in Chicken Tissues, Application of efficient-valid-green (EVG) Framework as a Competence ToolJournal of Chromatography A, 2024
- A case report on fatal intoxication by tapentadol: Study of distribution and metabolismForensic Science International, 2021
- Enantioselective analysis of venlafaxine and its active metabolites: A review on the separation methodologiesBiomedical Chromatography, 2020
- Tramadol abuse among workers in an industrial city in mid-Nile Delta region, EgyptEnvironmental Science and Pollution Research, 2020
- Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 InhibitorsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- Revisiting Tramadol: A Multi-Modal Agent for Pain ManagementCNS Drugs, 2019
- Tramadol: Understanding the Risk of Serotonin Syndrome and SeizuresThe American Journal of Medicine, 2018
- Development and validation of a sensitive UHPLC‐MS/MS method for the simultaneous analysis of tramadol, dextromethorphan chlorpheniramine and their major metabolites in human plasma in forensic context: application to pharmacokineticsBiomedical Chromatography, 2014
- Abuse of prescription drugs and the risk of addictionDrug and Alcohol Dependence, 2006
- Major increases in opioid analgesic abuse in the United States: Concerns and strategiesDrug and Alcohol Dependence, 2006